Status:

COMPLETED

Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease

Lead Sponsor:

National University Hospital, Singapore

Conditions:

Parkinson Disease

Eligibility:

All Genders

21+ years

Phase:

PHASE2

PHASE3

Brief Summary

The investigators hypothesise that measuring biomarkers of oxidative damage could better inform investigators on the potential merits (and pitfalls) of CoQ10 supplementation in PD subjects.

Detailed Description

Subjects with idiopathic PD will be recruited to a 10-week dose escalation study. Each dosage (400mg/day, 800mg/day, 1200/day and 2400mg/day) will be consumed daily for two weeks. Information on safet...

Eligibility Criteria

Inclusion

  • idiopathic Parkinson disease
  • age \>21 years
  • able to provide written informed consent

Exclusion

  • diabetes mellitus, stroke, cardiac and renal diseases and cigarette smoking
  • major psychiatric disorder or drug and/or alcohol abuse/dependence
  • regular use of antioxidants, dietary supplements, traditional Chinese remedies, non-steroidal anti-inflammatory drugs or immunosuppressive drugs

Key Trial Info

Start Date :

June 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT01892176

Start Date

June 1 2012

End Date

December 1 2012

Last Update

July 10 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National University Health System

Singapore, Singapore, Singapore, 119228

Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease | DecenTrialz